We are harnessing the power of mRNA to create a new category of medicines and a company that maximizes its impact on human health. We are currently focusing on five therapeutic areas – infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases.
What is a modality?
When we identify technologies that we believe could enable a new group of potential mRNA medicines with shared features, we call that group a modality. While the programs within a modality may target diverse diseases, they share similar mRNA characteristics, delivery technologies and manufacturing processes.
Infectious disease vaccines
Systemic secreted & cell surface therapeutics
Localized regenerative therapeutics
Systemic intracellular therapeutics
Inhaled pulmonary therapeutics
We have created seven modalities to date, but we are relentlessly working to grow this number as we discover mRNA medicines.
The world needs novel, innovative approaches to address both known and future infectious disease threats.
We are harnessing the body’s immune system to identify and kill cancer cells in the same way the immune system identifies and targets infections.
Moderna recognizes the impact of rare diseases on patients and their families, particularly when the disease lacks any effective treatment options.
We continue to explore the application of mRNA in the potential treatment of cardiovascular and other ischemic vascular diseases with the goal of addressing serious unmet needs to improve patients’ lives.
We are developing several potential mRNA therapeutics that we believe have the potential to help the millions of patients battling autoimmune diseases.
We are pleased to offer the opportunity to support research fellowships in order to further research in the area of mRNA medicines, as well as in disease areas currently under investigation by Moderna.